Investor Relations

Latest News

Jan 25, 2022

DiaMedica Therapeutics to Present Research at International Stroke Conference

View Press Release

Jan 5, 2022

DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

Dec 13, 2021

DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event

View All News

DiaMedica Corporate Presentation

View Presentation

Feb 9 – Feb 11, 2022

International Stroke Conference 2022

View All

Feb 10, 2022 12:30 pm EST – 1:15 pm EST

American Heart Association 2022 International Stroke Conference

View Event Add to Calendar View All

Mar 1 – Mar 3, 2022

4th Chronic Kidney Disease Drug Development Summit (previously CKD3)

View All

Most Recent Business Quarterly Update

View Q3 2021 Update

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

View Board of Directors

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447